How many courses of trastuzumab should be used?

Fam-trastuzumab deruxtecan-nxki is a targeted therapy drug used to treat HER2-positive breast cancer or other HER2-positive solid tumors, including non-small cell lung cancer, gastric cancer, etc.. It is an antibody-drug complex, which is composed of an antibody against the HER2 receptor and an inhibitor. It can act as a targeted therapy against cancer cells that overexpress the HER2 receptor. Trastuzumab is usually administered as an intravenous injection, and the dose and duration of each course may vary based on individual circumstances.

Typically, treatment options will be determined based on the severity of the condition, the patient's overall health, and other individualized factors. In clinical trials, trastuzumab is typically administered as a loading dose every three weeks, followed by a maintenance dose every three weeks until disease progression or intolerance. According to clinical trial results, trastuzumab can significantly extend survival and improve patients' quality of life. However, the actual course of medication may vary based on individual patient differences, severity of condition, and physician recommendations. Some patients may require longer treatment, while others may achieve disease control in a shorter period of time.

Therefore, the patient's specific treatment plan for trastuzumab should be determined by a professional doctor based on the patient's specific situation and needs. During the treatment process, the patient should pay close attention to his or her physical condition and communicate with the doctor in a timely manner in order to adjust the treatment plan and obtain the best treatment effect.